norethindrone acetate has been researched along with Endometrioma in 37 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
Endometrioma: An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate patient satisfaction at 6-months dienogest (DNG) treatment in women with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months of norethisterone acetate (NETA) therapy." | 9.19 | Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. ( Ferrero, S; Morotti, M; Remorgida, V; Sozzi, F; Venturini, PL, 2014) |
| "Women with pain symptoms caused by rectovaginal endometriosis were treated with letrozole (2." | 9.15 | Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. ( Ferrero, S; Gillott, DJ; Remorgida, V; Venturini, PL, 2011) |
| "The combination drug regimen was more effective in reducing pain and deep dyspareunia than norethisterone acetate; however, letrozole caused a higher incidence of adverse effects, cost more and did not improve patients' satisfaction or influence recurrence of pain." | 9.14 | Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. ( Camerini, G; Ferrero, S; Ragni, N; Remorgida, V; Seracchioli, R; Venturini, PL, 2009) |
| "To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis." | 9.11 | Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. ( Chiodini, A; Crosignani, PG; De Giorgi, O; Pasin, R; Pietropaolo, G; Vercellini, P, 2005) |
| "To determine the role of an aromatase inhibitor, letrozole, in the treatment of reproductive-age women with endometriosis and associated chronic pelvic pain." | 9.11 | Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. ( Ailawadi, RK; Bulun, SE; Gurates, B; Jobanputra, S; Kataria, M, 2004) |
| "Goserelin diminished significantly the symptoms and laparoscopic scores of endometriosis." | 9.08 | Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. ( Hagman, E; Kiilholma, P; Kivinen, S; Korhonen, M; Tuimala, R, 1995) |
| "To study the efficacy of long-term treatment with norethindrone acetate (NETA) in patients with rectovaginal endometriosis." | 7.85 | Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. ( Biscaldi, E; Calanni, L; Ferrero, S; Morotti, M; Racca, A; Stabilini, C; Vellone, VG; Venturini, PL, 2017) |
| "NET-A in a dose greater than 10 mg/d might be associated with increased risk for hepatic adenomas, likely due to peripheral conversion to ethinyl estradiol." | 7.85 | Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate. ( Brady, PC; Laufer, MR; Missmer, SA, 2017) |
| "To assess the proportion of patients satisfied with their treatment before and after a systematic change from norethindrone acetate to dienogest as the first-line progestin for symptomatic endometriosis." | 7.83 | Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. ( Alberico, D; Bracco, B; Dhouha, D; Mosconi, P; Roberto, A; Somigliana, E; Vercellini, P, 2016) |
| "To evaluate the efficacy and tolerability of norethindrone acetate (NA) as single-agent hormonal therapy for suppression of endometriosis symptoms in adolescents and young adults." | 7.78 | Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. ( Berry, KF; Kaser, DJ; Laufer, MR; Missmer, SA, 2012) |
| "The administration of letrozole and norethisterone acetate reduces pain and gastrointestinal symptoms of women with colorectal endometriosis, particularly when patients suffer from symptoms mimicking diarrhoea-predominant irritable bowel syndrome." | 7.76 | Letrozole and norethisterone acetate in colorectal endometriosis. ( Biscaldi, E; Camerini, G; Ferrero, S; Ragni, N; Remorgida, V; Seracchioli, R; Venturini, PL, 2010) |
| "Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation." | 6.48 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. ( Chwalisz, K; Stanczyk, FZ; Surrey, E, 2012) |
| "Endometriosis affects over 10 million women in the United States." | 5.43 | Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy. ( Bonafede, M; Castelli-Haley, J; Farr, AM; Soliman, AM; Winkel, C, 2016) |
| "To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agonists for endometriosis." | 5.20 | Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. ( DiVasta, AD; Feldman, HA; Gordon, CM; Hornstein, MD; Laufer, MR; Sadler Gallagher, J; Stokes, NA, 2015) |
| "To evaluate patient satisfaction at 6-months dienogest (DNG) treatment in women with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months of norethisterone acetate (NETA) therapy." | 5.19 | Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. ( Ferrero, S; Morotti, M; Remorgida, V; Sozzi, F; Venturini, PL, 2014) |
| "Women with pain symptoms caused by rectovaginal endometriosis were treated with letrozole (2." | 5.15 | Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. ( Ferrero, S; Gillott, DJ; Remorgida, V; Venturini, PL, 2011) |
| "The combination drug regimen was more effective in reducing pain and deep dyspareunia than norethisterone acetate; however, letrozole caused a higher incidence of adverse effects, cost more and did not improve patients' satisfaction or influence recurrence of pain." | 5.14 | Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. ( Camerini, G; Ferrero, S; Ragni, N; Remorgida, V; Seracchioli, R; Venturini, PL, 2009) |
| "To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis." | 5.11 | Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. ( Chiodini, A; Crosignani, PG; De Giorgi, O; Pasin, R; Pietropaolo, G; Vercellini, P, 2005) |
| "To determine the role of an aromatase inhibitor, letrozole, in the treatment of reproductive-age women with endometriosis and associated chronic pelvic pain." | 5.11 | Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. ( Ailawadi, RK; Bulun, SE; Gurates, B; Jobanputra, S; Kataria, M, 2004) |
| "GnRH agonist and norethindrone acetate alone or combined with low-dose conjugated equine estrogens administered to symptomatic endometriosis patients for 12 months provides extended pain relief and bone mineral density preservation after completion of therapy." | 5.10 | Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. ( Hornstein, MD; Surrey, ES, 2002) |
| "Goserelin diminished significantly the symptoms and laparoscopic scores of endometriosis." | 5.08 | Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. ( Hagman, E; Kiilholma, P; Kivinen, S; Korhonen, M; Tuimala, R, 1995) |
| "This patient preference prospective study was designed to compare patients' satisfaction in women with endometriosis treated either by an extended-cycle oral contraception (OC) or by norethindrone acetate (NETA)." | 3.88 | Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique ( Barra, F; Ferrero, S; Leone Roberti Maggiore, U; Scala, C; Venturini, PL, 2018) |
| "NET-A in a dose greater than 10 mg/d might be associated with increased risk for hepatic adenomas, likely due to peripheral conversion to ethinyl estradiol." | 3.85 | Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate. ( Brady, PC; Laufer, MR; Missmer, SA, 2017) |
| "To study the efficacy of long-term treatment with norethindrone acetate (NETA) in patients with rectovaginal endometriosis." | 3.85 | Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. ( Biscaldi, E; Calanni, L; Ferrero, S; Morotti, M; Racca, A; Stabilini, C; Vellone, VG; Venturini, PL, 2017) |
| "To assess the proportion of patients satisfied with their treatment before and after a systematic change from norethindrone acetate to dienogest as the first-line progestin for symptomatic endometriosis." | 3.83 | Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. ( Alberico, D; Bracco, B; Dhouha, D; Mosconi, P; Roberto, A; Somigliana, E; Vercellini, P, 2016) |
| "To compare the efficacy of norethisterone acetate (NETA; group N) or letrozole combined with NETA (group L) in treating endometriotic ovarian cysts." | 3.80 | Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. ( Ferrero, S; Leone Roberti Maggiore, U; Remorgida, V; Venturini, PL, 2014) |
| "To evaluate the efficacy and tolerability of norethindrone acetate (NA) as single-agent hormonal therapy for suppression of endometriosis symptoms in adolescents and young adults." | 3.78 | Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. ( Berry, KF; Kaser, DJ; Laufer, MR; Missmer, SA, 2012) |
| "The administration of letrozole and norethisterone acetate reduces pain and gastrointestinal symptoms of women with colorectal endometriosis, particularly when patients suffer from symptoms mimicking diarrhoea-predominant irritable bowel syndrome." | 3.76 | Letrozole and norethisterone acetate in colorectal endometriosis. ( Biscaldi, E; Camerini, G; Ferrero, S; Ragni, N; Remorgida, V; Seracchioli, R; Venturini, PL, 2010) |
| "BMD at the hip was normal in most adolescents with endometriosis who were receiving a GnRH-agonist plus add-back therapy with norethindrone acetate." | 3.74 | Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. ( Divasta, AD; Gordon, CM; Laufer, MR, 2007) |
| " Treatment with GnRHa combined with add-back therapy led to improved QOL, with no worsening of mood or menopausal side effects." | 2.84 | The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial. ( DiVasta, AD; Feldman, HA; Gordon, CM; Hornstein, MD; Laufer, MR; Sadler Gallagher, J; Stokes, NA, 2017) |
| "Endometriosis is a chronic estrogen and progestogen responsive inflammatory disease associated with pain symptoms and infertility." | 2.58 | Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. ( Barra, F; Ferrero, S; Scala, C, 2018) |
| " Biologic data and limited clinical evidence support a potential adverse effect of long-term use of OCPs on the progression of endometriosis." | 2.55 | Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. ( Casper, RF, 2017) |
| "Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation." | 2.48 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. ( Chwalisz, K; Stanczyk, FZ; Surrey, E, 2012) |
| " With further investigation, such regimens may allow safe prolongation of GnRH analogue use without sacrificing efficacy in those endometriosis patients with severe pelvic pain." | 2.40 | Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient. ( Surrey, ES, 1998) |
| "Progestins are first-line, on-label treatments of endometriosis that may have direct effects on endometriotic lesions through these nuclear receptors." | 1.46 | The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. ( Bersinger, NA; Facchinetti, F; Grandi, G; McKinnon, BD; Mueller, MD, 2017) |
| "Endometriosis is an estrogen-dependent inflammatory disease." | 1.43 | Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. ( Bersinger, N; Cagnacci, A; Grandi, G; McKinnon, B; Mueller, M; Nirgianakis, K; Papadia, A, 2016) |
| "Endometriosis affects over 10 million women in the United States." | 1.43 | Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy. ( Bonafede, M; Castelli-Haley, J; Farr, AM; Soliman, AM; Winkel, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 27 (72.97) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morotti, M | 2 |
| Venturini, PL | 9 |
| Biscaldi, E | 3 |
| Racca, A | 1 |
| Calanni, L | 1 |
| Vellone, VG | 1 |
| Stabilini, C | 1 |
| Ferrero, S | 11 |
| Grandi, G | 2 |
| Mueller, MD | 1 |
| Bersinger, NA | 1 |
| Facchinetti, F | 1 |
| McKinnon, BD | 1 |
| Vercellini, P | 6 |
| Ottolini, F | 2 |
| Frattaruolo, MP | 4 |
| Buggio, L | 2 |
| Roberto, A | 3 |
| Somigliana, E | 5 |
| Scala, C | 3 |
| Leone Roberti Maggiore, U | 3 |
| Barra, F | 2 |
| Jones, GL | 1 |
| Consonni, D | 2 |
| Alberico, D | 2 |
| Fedele, L | 2 |
| Remorgida, V | 8 |
| Sozzi, F | 1 |
| DiVasta, AD | 3 |
| Feldman, HA | 2 |
| Sadler Gallagher, J | 2 |
| Stokes, NA | 2 |
| Laufer, MR | 5 |
| Hornstein, MD | 3 |
| Gordon, CM | 3 |
| Agarwal, SK | 1 |
| Foster, WG | 1 |
| Bracco, B | 1 |
| Mosconi, P | 1 |
| Dhouha, D | 1 |
| Soliman, AM | 1 |
| Bonafede, M | 1 |
| Farr, AM | 1 |
| Castelli-Haley, J | 1 |
| Winkel, C | 1 |
| Mueller, M | 1 |
| Bersinger, N | 1 |
| Papadia, A | 1 |
| Nirgianakis, K | 1 |
| Cagnacci, A | 1 |
| McKinnon, B | 1 |
| Brady, PC | 1 |
| Missmer, SA | 2 |
| Casper, RF | 1 |
| Camerini, G | 3 |
| Seracchioli, R | 2 |
| Ragni, N | 3 |
| Fuldeore, MJ | 1 |
| Marx, SE | 1 |
| Chwalisz, K | 2 |
| Smeeding, JE | 1 |
| Brook, RA | 1 |
| Roman, H | 1 |
| Gillott, DJ | 1 |
| Kaser, DJ | 1 |
| Berry, KF | 1 |
| Surrey, E | 1 |
| Stanczyk, FZ | 1 |
| De Giorgi, O | 2 |
| Di Luca, M | 1 |
| Ailawadi, RK | 1 |
| Jobanputra, S | 1 |
| Kataria, M | 1 |
| Gurates, B | 1 |
| Bulun, SE | 1 |
| Pietropaolo, G | 1 |
| Pasin, R | 1 |
| Chiodini, A | 1 |
| Crosignani, PG | 1 |
| Kiilholma, P | 1 |
| Tuimala, R | 1 |
| Kivinen, S | 1 |
| Korhonen, M | 1 |
| Hagman, E | 1 |
| Edmonds, DK | 1 |
| Marik, JJ | 1 |
| Surrey, ES | 2 |
| Pierce, SJ | 1 |
| Gazvani, MR | 1 |
| Farquharson, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assisted Reproductive Technology (ART) and Pregnancy Outcomes in Women With Adenomyosis (Internal Endometriosis) According to Stimulation Protocol in Relation to Immunological and Endometrial Features: a Prospective, Randomized Study[NCT05937490] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-03-27 | Recruiting | ||
| The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial[NCT00474851] | Phase 2 | 53 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Effects of the Supplementation of α-lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D to Women Presenting Risk Factor for Pre-term Birth[NCT03952533] | 122 participants (Actual) | Interventional | 2019-05-05 | Completed | |||
| A Randomized Controlled Trial of a Nutritional Intervention for Endometriosis[NCT05175248] | 120 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms[NCT03991520] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-06-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjusted mean change in total body areal bone mineral density (aBMD) over the 12 month trial (NCT00474851)
Timeframe: Baseline to 12 months
| Intervention | g/cm^2 (Mean) |
|---|---|
| Intervention Group | 0.01 |
| Placebo Group | -0.11 |
(NCT00474851)
Timeframe: Baseline to 12 months
| Intervention | g (Mean) |
|---|---|
| Intervention Group | 37 |
| Placebo Group | 15 |
4 reviews available for norethindrone acetate and Endometrioma
| Article | Year |
|---|---|
Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis.
Topics: Administration, Oral; Endometriosis; Female; Humans; Medroxyprogesterone Acetate; Norethindrone; Nor | 2018 |
Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.
Topics: Administration, Oral; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Endometriosis; | 2017 |
The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Topics: Bone Density; Endometriosis; Estrogens; Female; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; | 2012 |
Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient.
Topics: Endometriosis; Estrogens; Estrogens, Conjugated (USP); Female; Genital Diseases, Female; Gonadotropi | 1998 |
14 trials available for norethindrone acetate and Endometrioma
| Article | Year |
|---|---|
Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment.
Topics: Adult; Contraceptives, Oral; Endometriosis; Female; Follow-Up Studies; Humans; Nandrolone; Norethind | 2014 |
Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Resorption; Dose-Response Relationship, Drug; | 2015 |
Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back.
Topics: Adult; Aromatase Inhibitors; Cohort Studies; Drug Therapy, Combination; Endometriosis; Female; Human | 2015 |
The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Topics: Adolescent; Boston; Contraceptives, Oral, Synthetic; Double-Blind Method; Drug Therapy, Combination; | 2017 |
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.
Topics: Adult; Analgesics, Non-Narcotic; Aromatase Inhibitors; Drug Therapy, Combination; Dysmenorrhea; Dysp | 2009 |
Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial.
Topics: Adult; Aromatase Inhibitors; Drug Therapy, Combination; Dyspareunia; Endometriosis; Female; Humans; | 2011 |
Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction.
Topics: Adult; Body Mass Index; Cohort Studies; Coitus; Dyspareunia; Endometriosis; Female; Humans; Logistic | 2012 |
Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.
Topics: Adult; Aromatase Inhibitors; Calcium; Cholecalciferol; Contraceptives, Oral, Sequential; Contracepti | 2013 |
Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study.
Topics: Adult; Analysis of Variance; Aromatase Inhibitors; Bone Density; Contraceptives, Oral, Synthetic; En | 2004 |
Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.
Topics: Adolescent; Adult; Confidence Intervals; Drug Therapy, Combination; Endometriosis; Estrogen Replacem | 2005 |
Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endometrios | 1995 |
Add-back therapy in the treatment of endometriosis: the European experience.
Topics: Administration, Cutaneous; Bone Density; Double-Blind Method; Drug Combinations; Endometriosis; Estr | 1996 |
Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
Topics: Adult; Bone Density; Drug Implants; Drug Therapy, Combination; Endometriosis; Estradiol; Female; Fol | 2000 |
Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Topics: Adult; Bone Density; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; | 2002 |
19 other studies available for norethindrone acetate and Endometrioma
| Article | Year |
|---|---|
Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis.
Topics: Adult; Cohort Studies; Dyspareunia; Endometriosis; Female; Humans; Norethindrone; Norethindrone Acet | 2017 |
The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis.
Topics: Adult; Cytokines; Endometriosis; Endometrium; Female; Humans; Inflammation; Medroxyprogesterone Acet | 2017 |
Is Shifting to a Progestin Worthwhile When Estrogen-Progestins Are Inefficacious for Endometriosis-Associated Pain?
Topics: Adolescent; Adult; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Desogestrel; Endometriosis | 2018 |
Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique
Topics: Adult; Contraceptives, Oral, Synthetic; Drug Combinations; Endometriosis; Ethinyl Estradiol; Female; | 2018 |
Shifting from Oral Contraceptives to Norethisterone Acetate, or Vice Versa, because of Drug Intolerance: Does the Change Benefit Women with Endometriosis?
Topics: Adult; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Drug Hypersensitivity; Drug Substituti | 2018 |
Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life.
Topics: Adolescent; Adult; Cohort Studies; Depression; Dyspareunia; Endometriosis; Female; Humans; Laparosco | 2013 |
Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study.
Topics: Adult; Aromatase Inhibitors; Drug Therapy, Combination; Dysmenorrhea; Dyspareunia; Endometriosis; Fe | 2014 |
Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.
Topics: Adult; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Endometriosis; Female; Humans; Nandrolo | 2016 |
Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Topics: Adult; Bone Density; Drug Therapy, Combination; Endometriosis; Estrogens; Female; Gonadotropin-Relea | 2016 |
Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Microenvironment; Cytokines; Endometrio | 2016 |
Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Microenvironment; Cytokines; Endometrio | 2016 |
Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Microenvironment; Cytokines; Endometrio | 2016 |
Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Microenvironment; Cytokines; Endometrio | 2016 |
Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate.
Topics: Adenoma; Adolescent; Adult; Contraceptives, Oral, Hormonal; Endometriosis; Ethinyl Estradiol; Female | 2017 |
Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study.
Topics: Adult; Colonic Diseases; Endometriosis; Female; Humans; Norethindrone; Norethindrone Acetate; Pain; | 2010 |
Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Topics: Adult; Contraceptives, Oral, Synthetic; Databases, Factual; Endometriosis; Estrogens; Female; Gonado | 2010 |
Letrozole and norethisterone acetate in colorectal endometriosis.
Topics: Abdominal Pain; Aromatase Inhibitors; Colonic Diseases; Diarrhea; Drug Therapy, Combination; Dyspare | 2010 |
Endometriosis presenting with hemorrhagic ascites.
Topics: Ascites; CA-125 Antigen; Contraceptives, Oral, Synthetic; Diagnostic Imaging; Endometriosis; Female; | 2011 |
Oral contraceptives and endometriosis.
Topics: Contraceptives, Oral; Endometriosis; Female; Humans; Norethindrone; Norethindrone Acetate; Recurrenc | 2011 |
Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms.
Topics: Adolescent; Adult; Contraceptives, Oral, Synthetic; Endometriosis; Female; Humans; Metrorrhagia; Nor | 2012 |
Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Cohort Studies; Endometriosis; Female; Gona | 2007 |
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study.
Topics: Drug Therapy, Combination; Endometriosis; Estrogens, Conjugated (USP); Female; Humans; Leuprolide; N | 1998 |
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study.
Topics: Drug Therapy, Combination; Endometriosis; Estrogens, Conjugated (USP); Female; Humans; Leuprolide; N | 1998 |
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study.
Topics: Drug Therapy, Combination; Endometriosis; Estrogens, Conjugated (USP); Female; Humans; Leuprolide; N | 1998 |
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study.
Topics: Drug Therapy, Combination; Endometriosis; Estrogens, Conjugated (USP); Female; Humans; Leuprolide; N | 1998 |